The experiments show that ligand-dependent activation of PPARβ/δ causes a BCL6-dependent repression of MMP-9 and other genes involved in cancer metastasis and decreases indices of cell migration, suggesting that PPARβ/δ agonists may be a beneficial tool in the prevention and treatment of pancreatic cancer. This evidence concerns the gene MMP9 and cancer.